首页 > 用药指导 > 文章详情

安立生坦片进口药

发布时间:2023-11-01 14:43:00 阅读:1447 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

安立生坦

安立生坦 生产厂家:印度西普拉(Cipla)制药公司 功能主治:治疗肺动脉高压的ETAR拮抗剂,一年生存率高 用法用量:用法用量  必须由在肺动脉高压治疗方面有经验的医生决定是否开始本药治疗,并对治疗过程进行监测。  成人剂量  起始剂量为空腹或进餐后口服 5 mg 每日一次;如果耐受则可考虑调整为 10 mg 每日一次。  药片可在空腹或进餐后服用。  不能对药片进行掰半、压碎、或咀嚼。  没有在肺动脉高压患者中进行过高于 10 mg 每日一次剂量的研究。  在开始使用凡瑞克治疗前和治疗的过程中要进行肝功能的监测(见【注意事项】部分)。  育龄期女性  女性只有在妊娠测试阴性、以及使用两种合适的避孕方法进行避孕的情况下才能接受治疗,但如果患者已行输卵管结扎术或选择使用 T 型铜 380A IUD 或 LNg 20 IUS 进行避孕,则不需要采取另外的避孕措施。  接受凡瑞克治疗的育龄期女性应该每月进行妊娠测试(见【禁忌】和【注意事项】部分)。  已存在的肝损害  目前尚无关于已存在的肝损害对安立生坦药代动力学影响的研究。  因为体内和体外证据都表明,安立生坦的清除很大程度上依赖肝脏代谢和胆汁排泄,因此肝脏损害预计会对安立生坦的药代动力学产生明显的影响。  不建议中度或重度肝功能损害患者使用凡瑞克。  目前没有关于凡瑞克在已有轻度肝功能损害的患者中应用的资料;然而,在此类患者中安立生坦的暴露量可能会升高。  肝转氨酶升高  其它内皮素受体拮抗剂(ERAs)与转氨酶(AST,ALT)升高、肝毒性和肝衰竭病例相关。  对于开始服用凡瑞克后发生肝损伤的患者,应全面调查其肝损伤的诱因。  如转氨酶升高 > 5x ULN 或转氨酶升高还伴随胆红素 > 2x ULN,或伴有肝功能不全的症状或体征,并且可排除其他原因,则停用凡瑞克。  与环孢素 A 合用  与环孢素 A 合用时,凡瑞克的剂量应控制在 5 mg 每日一次以内(见【药物相互作用】、【药代动力学】部分)。
查看详情
  安立生坦(Ambrisentan)是一种内皮素受体拮抗剂,通过抑制内皮素的作用,减少肺动脉收缩性,降低肺动脉压力和血管阻力。内皮素是一种血管紧张素的形态,在肺动脉高压患者中高度活跃,容易导致血管收缩和肺动脉不适当扩张。而安立生坦通过选择性地拮抗内皮素受体,能够有效地减少肺动脉内皮素的活性,从而降低肺动脉的压力,缓解患者的症状。
  作为一种进口药,安立生坦片具有许多优势。首先,安立生坦片的疗效已得到了全球范围内的大规模研究和临床试验的验证。大量的研究结果表明,安立生坦片能够显著地改善肺动脉高压患者的生活质量,减轻症状和增加运动能力。其次,安立生坦片具有很好的安全性和耐受性,对身体的副作用相对较低。临床研究发现,除少数个案外,安立生坦片并没有出现严重的不良反应,大多数患者能够良好地耐受该药物。最后,安立生坦片的规格多样,满足不同患者的需求。无论是治疗早期或晚期的肺动脉高压,还是单独使用或与其他药物联合使用,安立生坦片都能提供多种剂量和药物组合。
  安立生坦片在治疗肺动脉高压方面具有显著的疗效。在临床试验中,安立生坦片被证明能够显著降低肺动脉压力和血管阻力,改善患者的症状和生活质量。与安慰剂相比,安立生坦片能够显著减少肺动脉高压发作的频率和严重程度,并延长患者的生存时间。此外,安立生坦片还可以减少住院治疗的次数,降低医疗费用和患者的经济负担。
  总的来说,安立生坦片进口药是一种高效、安全和可靠的药物,用于治疗肺动脉高压。它通过降低肺动脉压力和血管阻力,显著缓解患者的症状和疼痛,提高其生活质量。作为一种进口药,安立生坦片具有很好的疗效、安全性和耐受性。不仅在国外得到广泛应用,也逐渐受到国内患者和医生的认可和选择。然而,作为一种处方药物,安立生坦片必须在医生的指导下使用,严格遵循剂量和使用方法,以确保患者的安全和疗效。
  【参考译文】
  Ambrisentan tablets, an imported medicine, are used to treat pulmonary arterial hypertension. It effectively alleviates the pain and symptoms of patients by reducing pulmonary artery pressure and vascular resistance. Ambrisentan is known for its high effectiveness, safety, and reliability. This article will discuss the characteristics of Ambrisentan tablets as an imported drug and their role in treating pulmonary arterial hypertension.
  Ambrisentan is an endothelin receptor antagonist that reduces pulmonary artery vasoconstriction and lowers pulmonary artery pressure and vascular resistance by inhibiting the action of endothelin. Endothelin is a form of angiotensin that is highly active in patients with pulmonary arterial hypertension and is prone to cause vascular constriction and inappropriate dilation of the pulmonary artery. Ambrisentan selectively blocks the endothelin receptor, effectively reducing the activity of endothelin in the pulmonary artery, thereby reducing pulmonary artery pressure and relieving symptoms in patients.
  As an imported drug, Ambrisentan tablets have many advantages. First, the effectiveness of Ambrisentan tablets has been verified by large-scale studies and clinical trials worldwide. Numerous studies have shown that Ambrisentan tablets can significantly improve the quality of life of patients with pulmonary arterial hypertension, reduce symptoms, and increase exercise capacity. Second, Ambrisentan tablets have good safety and tolerability, with relatively few side effects on the body. Clinical studies have found that, except for a few isolated cases, Ambrisentan tablets do not cause serious adverse reactions, and most patients can tolerate the drug well. Finally, Ambrisentan tablets come in various specifications to meet the needs of different patients. Whether for treating early or advanced pulmonary arterial hypertension, or for standalone use or combined use with other drugs, Ambrisentan tablets provide various doses and drug combinations.
  Ambrisentan tablets have shown remarkable efficacy in treating pulmonary arterial hypertension. In clinical trials, Ambrisentan tablets have been shown to significantly reduce pulmonary artery pressure and vascular resistance, improve symptoms, and enhance the quality of life of patients. Compared with a placebo, Ambrisentan tablets can significantly reduce the frequency and severity of pulmonary arterial hypertension attacks and prolong patients' survival. Additionally, Ambrisentan tablets can reduce hospitalization rates, lower medical expenses, and ease patients' financial burden.
  In conclusion, Ambrisentan tablets, as an imported drug, are efficient, safe, and reliable in treating pulmonary arterial hypertension. By reducing pulmonary artery pressure and vascular resistance, Ambrisentan tablets effectively relieve symptoms and pain, and improve patients' quality of life. As a prescription medicine, Ambrisentan tablets should be used under the guidance of doctors, strictly following the dosage and instructions, to ensure patient safety and effectiveness.